



International Alliance for
Biological Standardization

Frankfurt, Germany

December, 3-5 2024

4th Conference on Next Generation Sequencing for Adventitious Virus Detection in Biologics for Humans and Animal

2024 is a key year for globally considering NGS implementation with the recent publication of the revised ICHQ5A(R2) guideline and the expected publication of the EDQM/European Pharmacopoeia chapter for comments.

The 4th NGS meeting will continue to highlight current scientific data and knowledge with focus on NGS implementation for adventitious virus detection in biological products. Discussions will include capabilities of NGS for virus detection in different matrices and validation of the technical and bioinformatics steps involved in NGS for its applications in characterization and safety evaluation of biologics such as vaccines for human and veterinary use, gene and cell therapy products, and biotherapeutics.

The meeting will bring together representatives from industry, academia, technology providers, and international regulatory bodies for discussing the current applications of NGS for detection of adventitious viruses in biologics.

A one-day NGS training workshop to be associated to this conference is in preparation and further details will be communicated soon.

More information



www.iabs.org

Scientific Committee :

- **Arifa S. KHAN**, co-chair
FDA-CBER (FDA), U.S.A.
- **Laurent MALLET**, co-chair, EDQM, France
- **Pieter NEELS**, IABS Human Vaccine Committee Chair, Belgium
- **Johannes BLÜMEL**, PEI, Germany
- **Noémie DENEYER**, GSK, Belgium
- **Sigrid DE KEERSMAECKER**, Sciensano, Belgium
- **Blandine DE SAINT-VIS**, Boehringer-Ingelheim, France
- **Ivana KNEZEVIC**, WHO, Switzerland
- **Carine LOGVINOFF**, Sanofi, France
- **Marie MURPHY**, Eli Lilly, Ireland
- **Siemon NG**, Notch Therapeutics Canada
- **Yoji SATO**, NIHS, Japan
- **Michael WALL**, Health Canada